Michael Yang, CEO

Oct. 14 | 10:15am | BlueRock Therapeutics Ballroom

San Diego, CA


In-person Presentation

ViaCyte is a privately held clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells, and medical device systems for cell encapsulation and implantation. ViaCyte has the opportunity to use these technologies to address critical human diseases and disorders that can potentially be treated by replacing lost or malfunctioning cells or proteins. The company’s first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand the company’s efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte’s mission is to reduce the relentless burden of disease management, improve health outcomes, and enhance the quality of life for patients.

By using this website you agree to accept our Privacy Policy and Terms & Conditions